Medication evidence profile
Chlorzoxazone
Clinical overview
Chlorzoxazone has public medication-list entries in JARS 2025, BAAS 2019, Swe-ABS 2023, and KABS 2020 open validation supplement. These are 4 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | 2 |
| Yamada-ABS | Not listed |
| BAAS | 2 |
| Swe-ABS | 0 |
| GABS | Not listed |
| KABS | 0 |
| CALS | Not listed |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
4 of 7 public source versions contain an explicit medication-list entry for chlorzoxazone.
The recorded values differ across the source rows for chlorzoxazone. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.
Swe-ABS 2023 and KABS 2020 open validation supplement explicitly record zero. Those recorded zeros remain different from a missing entry.
Source labels and provenance · 4 observations
- Japanese Anticholinergic Risk Scale (JARS) 2025 English translation
Source label: Chlorzoxazone. Published value: 2.
Source version: JARS-2025
Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=M03BB03
Observation: JARS_2025_R0062; rating state: published_rating. - Brazilian Anticholinergic Activity Scale 2019
Source label: Chlorzoxazone. Published value: 2.
Source version: BAAS-2019
Source location: RC4 source recovery; recovery_scope=primary_table_complete
Observation: BAAS_2019_R0050; rating state: published_rating. - Swedish Anticholinergic Burden Scale 2023
Source label: Chlorzoxazone. Published value: 0.
Source version: SWE-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_expert_zero_complete
Observation: SWE_ABS_2023_R0108; rating state: published_rating. - KABS 2019 scale - 2020 open validation supplement
Source label: Chlorzoxazone. Published value: 0.
Source version: KABS-2020-validation-supplement
Source location: Additional file 1; category Musculoskeletal agents; table row 84
Observation: KABS2020_SUPP_0431; rating state: published_zero.
What this page does not establish
- No medication-list entry is available here from Yamada-ABS 2023, GABS 2018, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- No route inference unless present in the source label.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
- Nery RT, Reis AMM. Development of a Brazilian anticholinergic activity drug scale. Einstein (Sao Paulo). 2019;17(2):eAO4435. doi:10.31744/einstein_journal/2019AO4435. Open source
- Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
- Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Chlorzoxazone
Ask about this medication